<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659252</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5361</org_study_id>
    <nct_id>NCT04659252</nct_id>
  </id_info>
  <brief_title>CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid)</brief_title>
  <official_title>Circulating Tumour Protein Quantification From Capillary Blood for Patient Selfsampling and Safe Remote Monitoring of Multiple Myeloma During COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus (COVID-19) pandemic has brought severe challenges for myeloma patients.&#xD;
      Myeloma patients are considered ultra-high risk for COVID-19 and fall into the strictest&#xD;
      group for shielding. When on treatment, but also during times of active surveillance,&#xD;
      patients have to regularly and frequently leave shielding and visit the hospital for blood&#xD;
      tests to monitor their disese. This is specifically for quantification of circulating tumour&#xD;
      protein biomarker tests for paraprotein (PP) and/or serum free light chains (sFLCs) by&#xD;
      specialised biochemistry units.&#xD;
&#xD;
      This research aims to evaluate the potential use of an at-home patient administered technique&#xD;
      to sample blood. The purpose of the blood sampling technique is to monitor your disease&#xD;
      status. We want to test if it is possible to monitor a patient's disease status using this&#xD;
      alternative blood collection method when compared to monitoring disease status using the&#xD;
      traditional blood collection methods (venous blood sampling).&#xD;
&#xD;
      The new VAMS method is not intended to be used interchangeably or will not replace the&#xD;
      current method. This study is to evaluate an alternative sample type that may be used to&#xD;
      improve the patient pathway, especially during these uncertain times.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validated FLC</measure>
    <time_frame>6 months</time_frame>
    <description>Validated FLC method for use with VAMS that conforms to ISO15189:2012 accreditation</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>n/a - samples collected along routine care samples only</intervention_name>
    <description>This is a non-interventional study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple myeloma patients attending routine phlebotomy clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of a B-cell dyscrasia&#xD;
&#xD;
          2. Measurable disease by serum free light chain assay&#xD;
&#xD;
          3. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients &lt;21 years of age&#xD;
&#xD;
          2. Cognitive impairment&#xD;
&#xD;
          3. Non-B Cell Dyscrasia patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Boyd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloe Burrows</last_name>
    <phone>02089156773</phone>
    <email>chloe.burrows@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haemato-oncology Research Team</last_name>
    <email>HaemoncGT@rmh.nhs.uk</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

